Year archive

Grand Pharmaceutical Group Limited — 2024 filings

All 64 regulatory filings released by Grand Pharmaceutical Group Limited (512) in 2024, sourced directly from the official regulator.

64 Filings

2024 Period

2024 filings (64)

Filing	Released	Lang
CHANGE OF PRINCIPAL SHARE REGISTRAR AND TRANSFER AGENT IN BERMUDA Regulatory Filings	2024-12-24	English
VOLUNTARY ANNOUNCEMENT: NDA FOR A GLOBAL INNOVATIVE PRODUCT OF THE GROUP TREATED FOR DEMODEX BLEPHARITIS HAS BEEN ACCEPTED BY NMPA Regulatory Filings	2024-12-16	English
VOLUNTARY ANNOUNCEMENT: THE PHASE II CLINICAL STUDY IN CHINA OF THE GROUPS GLOBAL INNOVATIVE PRODUCT STC3141 HAS COMPLETED THE ENROLLMENT OF ALL PATIENTS Regulatory Filings	2024-12-13	English
VOLUNTARY ANNOUNCEMENT: THE GROUPS GLOBAL INNOVATIVE INTRAVASCULAR DUAL-MODE IMAGING SYSTEM NOVASYNC WAS APPROVED BY NMPA FOR COMMERCIALIZATION IN CHINA Regulatory Filings	2024-12-12	English
VOLUNTARY ANNOUNCEMENT: THE GROUP OBTAINED THE EXCLUSIVE DEVELOPMENT AND COMMERCIALIZATION RIGHTS OF THE WORLDS FIRST INNOVATIVE PRODUCT FOR THE TREATMENT OF DRY EYE Regulatory Filings	2024-12-11	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2024 Share Issue/Capital Change	2024-12-06	English
VOLUNTARY ANNOUNCEMENT: THE PHASE III CLINICAL STUDY CONDUCTED IN CHINA OF THE GLOBAL INNOVATIVE RDC TLX250-CDx HAS COMPLETED THE FIRST PATIENT ENROLLMENT AND DOSING Regulatory Filings	2024-11-28	English
CONTINUING CONNECTED TRANSACTION: 2024 DISTRIBUTION AGREEMENTS WITH SIRTEX MEDICA Capital/Financing Update	2024-11-15	English
VOLUNTARY ANNOUNCEMENT: THE PHASE III CLINICAL STUDY OF THE GROUPS GLOBAL INNOVATIVE OPHTHALMIC DRUG GPN00833 CONDUCTED IN CHINA HAS COMPLETED AND HAS SUCCESSFULLY MET CLINICAL ENDPOINT Regulatory Filings	2024-11-04	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 October 2024 Regulatory Filings	2024-11-01	English
VOLUNTARY ANNOUNCEMENT: THE FIRST ADJUSTABLE INTRACRANIAL STENT RETRIEVER PRODUCT THAT PRODUCED IN CHINA OF THE GROUP WAS APPROVED FOR COMMERCIALIZATION BY NMPA Regulatory Filings	2024-10-22	English
VOLUNTARY ANNOUNCEMENT - THE PHASE III CLINICAL TRIAL APPLICATION IN CHINA OF THE GLOBAL INNOVATIVE RDC DRUG OF THE GROUP ITM-11 WAS ACCEPTED BY NMPA Regulatory Filings	2024-10-14	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2024 Regulatory Filings	2024-10-02	English
Notification Letter and Reply Form to Non-registered Shareholders - Notice of publication of Interim Report Report Publication Announcement	2024-09-25	English
INTERIM REPORT 2024 Interim / Quarterly Report H1 2024	2024-09-25	English
Notification Letter and Reply Form to Registered Shareholders - Notice of publication of Interim Report Report Publication Announcement	2024-09-25	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2024 Regulatory Filings	2024-09-02	English
CLARIFICATION ANNOUNCEMENT IN RELATION TO APPOINTMENT OF DIRECTOR Board/Management Information	2024-08-30	English
List of Directors and their Role and Function Board/Management Information	2024-08-27	English
APPOINTMENT OF EXECUTIVE DIRECTOR Board/Management Information	2024-08-27	English
2024 INTERIM RESULTS ANNOUNCEMENT Interim / Quarterly Report H1 2024	2024-08-19	English
PROFIT ALERT Earnings Release H1 2024	2024-08-14	English
DATE OF BOARD MEETING Regulatory Filings	2024-08-08	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2024 Regulatory Filings	2024-08-01	English
VOLUNTARY ANNOUNCEMENT : THE GROUP COMPLETED THE ACQUISITION OF TIANJIN TANABE AND BAIJI PHARMACEUTICAL M&A Activity	2024-07-17	English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO ANNUAL REPORT 2023 Regulatory Filings	2024-07-05	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2024 Regulatory Filings	2024-07-05	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2024 Regulatory Filings	2024-07-02	English
RESIGNATION OF EXECUTIVE DIRECTOR AND APPOINTMENT OF NON-EXECUTIVE DIRECTOR Board/Management Information	2024-06-24	English
List of Directors and their Role and Function Board/Management Information	2024-06-24	English
VOLUNTARY ANNOUNCEMENT - THE PHASE I CLINICAL STUDY CONDUCTED IN CHINA OF THE GROUPS GLOBAL INNOVATIVE OPHTHALMIC DRUG GPN00884 HAS COMPLETED THE FIRST PATIENT ENROLLMENT Regulatory Filings	2024-06-11	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 4 JUNE 2024 Declaration of Voting Results & Voting Rights Announcements	2024-06-04	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2024 Regulatory Filings	2024-06-03	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2024 Regulatory Filings	2024-05-03	English
Notice of availability to Registered Shareholders and Reply Form Report Publication Announcement	2024-04-26	English
ESG Report 2023 Regulatory Filings	2024-04-26	English
Notice of availability to Non-registered Shareholders and Reply Form Report Publication Announcement	2024-04-26	English
Notice of Annual General Meeting AGM Information	2024-04-26	English
Proxy form for the annual general meeting to be held on Tuesday, 4 June 2024 or any adjournment thereof AGM Information	2024-04-26	English
Annual Report 2023 Regulatory Filings	2024-04-26	English
(1) GENERAL MANDATE TO REPURCHASE SHARES AND ISSUE NEW SHARES; (2) RE-ELECTION OF RETIRING DIRECTORS AND CONTINUOUS APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR SERVING MORE THAN NINE YEARS& AGM Information	2024-04-26	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2024 Regulatory Filings	2024-04-03	English
VOLUNTARY ANNOUNCEMENT: THE GROUP INTRODUCES A GLOBAL INNOVATIVE PRODUCT FOR THE TREATMENT OF DEMODEX BLEPHARITIS AND MEIBOMIAN GLAND DISEASE WITH DEMODEX MITES Capital/Financing Update	2024-03-27	English
Final dividend for the year ended 31 December 2023 Notice of Dividend Amount	2024-03-27	English
Final dividend for the year ended 31 December 2023 Notice of Dividend Amount	2024-03-26	English
THE GLOBAL INNOVATIVE RDC DRUG OF THE GROUP ITM-11 IS APPROVED TO CONDUCT PHASE III CLINICAL STUDY IN CHINA Regulatory Filings	2024-03-24	English
Final dividend for the year ended 31 December 2023 Notice of Dividend Amount	2024-03-21	English
Clarification Announcement in relation to Closure of Register of Members Regulatory Filings	2024-03-21	English
Final dividend for the year ended 31 December 2023 Notice of Dividend Amount	2024-03-19	English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023 Annual Report FY 2023	2024-03-19	English
DATE OF BOARD MEETING Regulatory Filings	2024-03-07	English
VOLUNTARY ANNOUNCEMENT: THE GROUPS GLOBAL INNOVATIVE OPHTHALMIC DRUG GPN00884 WAS APPROVED TO CONDUCT PHASE I CLINICAL STUDY IN CHINA Regulatory Filings	2024-03-07	English
VOLUNTARY ANNOUNCEMENT: THE NDA OF A GLOBAL INNOVATIVE HORMONE NANOSUSPENSION EYE DROPS WAS APPROVED BY THE FDA Regulatory Filings	2024-03-07	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 2024 Regulatory Filings	2024-03-04	English
CONNECTED TRANSACTION IN RELATION TO ENTERING INTO THE SECOND CONVERTIBLE LOAN AGREEMENT Capital/Financing Update	2024-03-04	English
ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES Capital/Financing Update	2024-02-29	English
Notification Letter to Registered Shareholders - New Arrangements on Dissemination of Corporate Communications Regulatory Filings	2024-02-27	English
Notification Letter and Request Form to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications Regulatory Filings	2024-02-27	English
VOLUNTARY ANNOUNCEMENT: THE NDA OF THE GROUPS GLOBAL INNOVATIVE PRODUCT RYALTRIS COMPOUND NASAL SPRAY SUBMITTED TO NMPA HAS BEEN ACCEPTED Regulatory Filings	2024-02-08	English
SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO DISCLOSEABLE TRANSACTION Capital/Financing Update	2024-02-04	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2024 Regulatory Filings	2024-02-02	English
VOLUNTARY ANNOUNCEMENT: THE INVESTIGATIONAL NEW DRUG APPLICATION IN CHINA OF THE GROUPS GLOBAL INNOVATIVE THERAPEUTIC TUMOR VACCINE ARC01 WAS APPROVED BY NMPA Regulatory Filings	2024-01-24	English
DISCLOSEABLE TRANSACTION IN RELATION TO THE ACQUISITION OF EQUITY INTEREST IN CHONGQING DUOPUTAI PHARMACEUTICAL TECHNOLOGY CO., LTD. M&A Activity	2024-01-15	English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2023 Regulatory Filings	2024-01-04	English

Filings by year

2026 23 filings
2025 64 filings
2024 64 filings
2023 69 filings
2022 49 filings
2021 72 filings
2020 50 filings
2019 44 filings
2018 72 filings
2017 40 filings
2016 45 filings
2015 36 filings
2014 32 filings
2013 44 filings
2012 46 filings
2011 28 filings
2010 63 filings
2009 28 filings
2008 41 filings
2007 21 filings
2006 28 filings
2005 35 filings
2004 54 filings
2003 41 filings
2002 40 filings
2001 23 filings
2000 13 filings
1999 4 filings